Inovio Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| INO | GNLX | PDSB | IVVD | TVGN | HBP.TO | |
|---|---|---|---|---|---|---|
| Market cap | 167.50M | 88.68M | 136.51M | 186.76M | 95.87M | 70.27M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -3.9 | -2.6 | -6.8 | -1.2 | — | -8.4 |
| Price/book | 30.6 | 5.4 | -20.3 | 1.0 | -1.4 | 4.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −27.51% | −75.51% | +55.80% | −61.71% | −77.45% | −54.00% |
| Today | −2.41% | +2.08% | −7.80% | +8.96% | −3.38% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All INO news ›Inovio: Upgrading To 'Buy' On Voceryq Accelerated Approval RRP And Competitive Advantages
Inovio Pharmaceuticals receives FDA Accelerated Approval for VOCERYQ in recurrent respiratory papillomatosis, prompting a rating upgrade. Click to read more. - Inovio Pharmaceuticals receives FDA Accelerated Approval for VOCERYQ [INO-3107]…
Key facts: Innoviva Reports Q3 Results; NUZOLVENCE Launches in U.S.; Three Products Named Prix Galien Finalists
TradingView Key facts: Innoviva Reports Q3 Results; NUZOLVENCE Launches in U.S.; Three Products Named Prix Galien Finalists - Innoviva (INVA) reported Q3 2026 revenue of $106.1 million, d
Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript
Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP November 2, 2026 8:00 AM EST Jennie Willson - Director of CommunicationsJacqueline Shea - CEO, President & DirectorMichael…
Inovio Pharmaceuticals Stock Soars Nearly 193% in Trading
Shares of Inovio Pharmaceuticals surged nearly 193% in a sharp move that put the biotech stock at the top of trending lists. The rally drew heavy trading interest from investors looking to catch the momentum. Moomoo's daily roundup…
Inovio Pharmaceuticals stock jumps 190.83% as hourly RSI reaches 82.54
Inovio Pharmaceuticals stock carries a bullish daily bias, yet its trend structure is not fully aligned… Inovio Pharmaceuticals stock carries a bullish daily bias, yet its trend structure is not fully aligned. Price stands above all three…
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious…
INO Jumps As FDA Approval And Court Win Shift Outlook
Inovio Pharmaceuticals Inc. stocks have been trading up by 246.95 percent amid heightened optimism from its latest clinical progress. Key Takeaways The FDA granted Inovio Pharmaceuticals accelerated approval for VOCERYQ, a DNA-based…
More from 1 other outlet
INO Stock Jumps As FDA Greenlights VOCERYQ And Court Win Lands $80.4M Judgment
Inovio Pharmaceuticals Inc. stocks have been trading up by 257.74 percent amid heightened optimism over its latest clinical progress. INO has been trading like a classic biotech battleground. On the daily chart, Inovio Pharmaceuticals…
Inovio shares surge 229% as FDA approves first commercial product
Inovio Pharmaceuticals Inc (NASDAQ:INO) shares jumped 229% to $1.98 after the drug developer said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, its first commercial product. The treatment aims to reduce…
Biotech Stock INOVIO (NASDAQ: INO) Leads Nasdaq Gainers Monday November 2nd
INOVIO leads Nasdaq gainers after the FDA granted accelerated approval for VOCERYQ to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis. Investorideas.com (www.investorideas.com) a trusted platform for…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com7
- seekingalpha.com4
- themarketsdaily.com3
- stockstotrade.com2
- timothysykes.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 26 articles, not a forecast.